Advancements in the treatment of T1D (new rapid and ultra-rapid insulin analogs, slow insulin with longer duration of action, insulin pumps, blood glucose sensors) have significantly improved the quality of life and overall life expectancy, primarily by limiting the progression of microvascular complications and by preventing acute metabolic complications. This evidence concerns the gene INS and type 1 diabetes mellitus.